Treating Pyelonephritis an Urosepsis With Pivmecillinam
Status:
Completed
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
Febrile urinary tract infections and urosepsis are common and potentially serious infections
that require effective antimicrobial treatment. The duration of parenteral treatment depends
on oral alternatives. These alternatives are few and due to antimicrobial resistance,
quinolones are "standard of care". The increased use of quinolones is concerning because of
its negative ecological aspects and it is confirmed an increasing incidence of resistant
E.coli to quinolones in Norwegian isolates.
Pivmecillinam is an antibiotic with high susceptibility to E.coli but the evidence for
treating febrile urinary tract infections is insufficient. This trial will investigate the
efficacy and safety of pivmecillinam in treating pyelonephritis and urosepsis caused by
E.coli.
The hypothesis is that urosepsis can safely be treated with pivmecillinam when it is given
after 2-3 days with empirical i.v. antibiotics.